Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA

Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model

(2012) Brian J. Werth et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model

(2012) Steven N. Leonard   PLoS One

Striking “Seesaw Effect” between Daptomycin Nonsusceptibility and β-Lactam Susceptibility in Staphylococcus haemolyticus

(2011) Carla Vignaroli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroPharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus

(2011) Mao Hagihara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of Antistaphylococcal  -Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding

(2011) A. Dhand et al.   CLINICAL INFECTIOUS DISEASES

Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure

(2011) Peter G. Kelley et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus

(2010) C. S. Lunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature

(2010) S. J. van Hal et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Development of Reduced Vancomycin Susceptibility in Methicillin‐SusceptibleStaphylococcus aureus

(2009) Satish K. Pillai et al.   CLINICAL INFECTIOUS DISEASES

Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureus

(2008) S. N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007)

(2008) M. J. Rybak et al.   JOURNAL OF CLINICAL MICROBIOLOGY